Three symptoms follow the level, the others do not
The European Male Ageing Study asked the question the right way round: rather than starting from a hormonal threshold, it looked for which symptoms actually shift with testosterone level in middle-aged and older men.
Eight symptoms emerged as associated with the level: weak morning erection, lower sexual desire, erectile dysfunction, inability to sustain vigorous physical activity, depression and fatigue, among others. But only the three sexual symptoms showed a syndromic association, that is, they vary together with the hormone. The more a man had of them, the lower his level.
The ranges recorded were 8.0 to 13.0 nmol/L for total testosterone and 160 to 280 pmol/L for the free fraction. Fatigue and mood are linked to the level without forming a syndrome with it, which means that a tired man is not therefore a man with a hormonal deficit.
The benefits of treatment, and its measured limits
The Testosterone Trials pooled seven coordinated placebo-controlled, double-blind trials, in 788 men with a mean age of 72 and a low level. Treatment brought testosterone to the middle of the young men's range from the third month and maintained it for twelve months.
The benefit on sexuality is clear: sexual activity, desire and erectile function all increase significantly. On physical function, the dedicated trial showed no difference in the proportion of men gaining at least 50 meters on the six-minute walk test; the difference appeared only when pooling the three trials, 20.5 percent against 12.6 percent.
And on what people most often come for, the result is negative. Testosterone brought no significant benefit on vitality measured by the FACIT-Fatigue scale. Mood and depressive symptoms improved slightly, no more.
Cardiovascular safety, measured in 5,204 men
The TRAVERSE trial was designed to answer the question that had blocked the subject for ten years. Mean treatment duration 21.7 months, mean follow-up 33 months, in hypogonadal men at high cardiovascular risk.
The primary cardiovascular outcome occurred in 7.0 percent of men on testosterone and 7.3 percent on placebo, hazard ratio 0.96, confidence interval 0.78 to 1.17, which establishes non-inferiority. The question of heart attack and stroke is therefore settled in a reassuring direction.
Three unfavorable signals nevertheless remain in the same trial: more atrial fibrillation, acute kidney injury and pulmonary embolism on testosterone. A meta-analysis of 23 trials and 9,280 men confirms the third point in another form: no difference in all-cause mortality, cardiovascular mortality, stroke or heart attack, but a clear increase in cardiac arrhythmias, relative risk 1.53.
The unexpected effects the trials revealed
Two TRAVERSE results deserve to be known because they go against common intuition. The first concerns bone. In 5,204 participants followed for a median of 3.19 years, a clinical fracture occurred in 3.50 percent of men on testosterone against 2.46 percent on placebo, hazard ratio 1.43. Incidence appeared higher on testosterone for all other fracture outcomes as well.
The second concerns the prostate, long presented as the major contraindication. Over 14,304 person-years, the incidence of high-grade prostate cancer was 0.19 percent on testosterone against 0.12 percent on placebo, with no significant difference, and the international prostate symptom score did not move. PSA, however, rises more on treatment, which requires monitoring.
On the benefit side, a solid effect appears on anemia. In 815 anemic men, correction at twelve months reached 45.0 percent on testosterone against 33.9 percent on placebo, and hemoglobin changes followed those of reported energy level.
Metabolism, a real benefit at the price of a real risk
The T4DM trial tested an appealing idea: treating with testosterone to prevent diabetes in men already engaged in a lifestyle program. Of 19,022 men pre-screened, 1,007 were randomized.
At two years, a two-hour glucose of 11.1 mmol/L or more during an oral glucose tolerance test was found in 21 percent of men on placebo against 12 percent on testosterone, relative risk 0.59. The effect was independent of baseline testosterone level, which is both interesting and disturbing: the benefit did not depend on an initial deficit.
The downside appears in the same table. A hematocrit above 54 percent, the safety threshold triggering an intervention, occurred in 22 percent of men on testosterone against 1 percent on placebo. A metabolic benefit obtained at the price of thicker blood in one man out of five is not decided outside medical monitoring.
What to do as a practitioner who is not a physician
Dosing, interpretation and prescription belong to the physician, without exception. A British synthesis of 35 studies and 5,601 participants notes moreover that it finds no signal of cardiac excess risk, while stressing that uncertainty concerns benefits as much as safety.
What a practitioner can do is precisely what the data support. First listen to what is described: three sexual symptoms that go together really do point somewhere, isolated fatigue does not. Then recall that testosterone did not improve vitality in the trial that measured it, which spares a disappointment and sometimes a useless purchase.
Finally work on what is within their scope and acts on the same complaints: strength, body composition, sleep and diet. Loss of muscle mass and strength has its own documented determinants, and a well-conducted first consultation questionnaire spots a correctable cause faster than a hormonal assay ordered blindly. In the face of persistent sexual symptoms, medical referral is the only correct answer.
Sources
- 1.Wu FC, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010.
- 2.Snyder PJ, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016.
- 3.Snyder PJ, et al. Lessons From the Testosterone Trials. Endocr Rev. 2018.
- 4.Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023.
- 5.Snyder PJ, et al. Testosterone Treatment and Fractures in Men with Hypogonadism. N Engl J Med. 2024.
- 6.Bhasin S, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023.
- 7.Pencina KM, et al. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023.
- 8.Wittert G, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021.
- 9.Braga MAP, et al. Long-Term Cardiovascular Safety of Testosterone-Replacement Therapy in Middle-Aged and Older Men: A Meta-analysis of Randomized Controlled Trials. Am J Cardiovasc Drugs. 2025.
- 10.Cruickshank M, et al. The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation. Health Technol Assess. 2024.
Reading studies is one thing, turning them into a plan is another
The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.
11 modules, €2,200. Enrol
Continue reading
Benjamin Sant
Co-founder of the School of Longevity
Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.
This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.
